Medical device and wound care company PolyNovo reports a 295 per cent slide in EBIT to post a $3.8m net loss after tax for the first half of the financial year.
PolyNovo said its first-half profit included the reversal of $4.7m in share awards and share options expense forfeited by the previous chief executive officer and chief operating officer on their resignations, and an unrealised forex gain of $400,000.
The group reported strong growth in the US with record firt-half sales of $22.8m, up 61 per cent.
PolyNovo recorded a 131 per cent jump in employee-related expenses to $17.7m.
Revenue of $29.6m was a 61.8 per cent increase on the first half of 2022.
PolyNovo said 8000 patients in the first six months of 2023 compared to near 10,000 patients through the full year 2022.